Orakl Oncology, a start-up spun out of the Gustave Roussy institute, announced a €30 million Series A on 12 November. Based in Villejuif, it grows miniature replicas of tumours from patients’ cells and combines them with artificial intelligence to predict whether a cancer drug is likely to succeed in a clinical trial. For drugmakers, the aim is to sort drug candidates earlier, before committing to the most expensive phases.
A Series A led by Norrsken and Singular
According to mind Health, the round, worth about $34 million, is co-led by the Norrsken and Singular funds, the latter having already led the company’s €11 million seed round. French Tech Journal lists the other participants: InfraVia, Serena, Teampact Ventures, Bpifrance, Plug and Play, Verve Ventures, Speedinvest and HCVC. The weekly roundup from Maddyness puts the amount at €30.7 million and adds All Iron Ventures as well as business angels.
The deal is the second largest in the weekly tally published by Maddyness on 13 November, behind Resilience’s €48 million. The outlet puts the total at €118.2 million across eight deals. Three of these start-ups, including Orakl, rely on AI and account for about 70% of the amounts raised.
Organoids to simulate trials
The method described by French Tech Journal starts from patient samples: the company grows tumour organoids, small three-dimensional structures that reproduce the behaviour of a tumour, and then tests molecules on them. These results are cross-referenced with genomic, molecular and clinical data to train predictive models. Pharmaceutical clients can then use them to choose their candidates, define the patient groups most likely to respond and reduce the risk of their programmes.
The company was founded by Fanny Jaulin, Gustave Ronteix and Diane-Laure Pagès. It claims 90% accuracy in retrospectively predicting the results of 40 published oncology trials. This figure is a company claim: French Tech Journal stresses that it has not been independently verified.
What the money will be used for
Again according to French Tech Journal, the funding is intended to:
- increase data production fivefold;
- add models for lung and stomach cancers, on top of existing work on colorectal and pancreatic cancers;
- build teams in the United States and the United Kingdom;
- deploy the platform in more than ten drug development programmes;
- step up research into new therapeutic targets.
The opening of teams across the Atlantic and across the Channel shows that the target clients are first and foremost large drugmakers, a large share of whose research decisions are made outside France.
What it changes
The development of a cancer drug often fails late, once human trials are under way. A tool able to rule out doomed molecules earlier, or to target patients better, could save manufacturers time and money. For patients, the hope would be that trials focus more on treatments suited to their tumour profile.
The funding also confirms investor interest in companies that combine laboratory biology and AI, often referred to as “techbio”. Finally, it illustrates the role of hospital institutes such as Gustave Roussy in creating French health start-ups.
The limits are real. A retrospective prediction on already published trials is not the same as prospective validation, in which the model announces a result before it is known. The sources consulted name no pharmaceutical client and give neither revenue nor headcount. The platform’s value will be judged on the programmes actually run with it.
Frequently asked questions
What is a tumour organoid?
It is a small three-dimensional cell structure, grown in the laboratory from a patient’s cells, that reproduces certain characteristics of their tumour. It is used to test the response to drugs outside the body.
Who funded Orakl Oncology?
The Series A is co-led by Norrsken and Singular, with participants including InfraVia, Serena, Bpifrance, Speedinvest, Verve Ventures, Teampact Ventures, Plug and Play and HCVC. Singular had already led the €11 million seed round.
Is the 90% accuracy proven?
No. It is a figure put forward by the company, obtained by comparing its predictions with the results of 40 already published trials. According to French Tech Journal, it has not been independently verified.
Sources
- Orakl Oncology lève 30 M€ en série A — mind Health, 2026-11-12
- French Tech Funding Wire November 16: Orakl Oncology's €30M Led 9 Deals For €75.6M — French Tech Journal, 2026-11-16
- Les startups françaises ont levé 118 millions d'euros cette semaine — Maddyness, 2026-11-13